Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SUPRABIOTICS

Financiado

Cerrado

Supramolecular Protective Groups Enabling Antibiotics and Bioimaging

The pharmaceutical sector has a huge demand for new active compounds including natural products to fill the drug pipelines and to stop the global decline in novel approved active pharmaceutical ingredients. Therefore, developing n... ver más

31/01/2022

DWI LEIBNIZINSTITU...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

DWI LEIBNIZINSTITUT FUR INTERAKTIVE MATERIALI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-01-31

ERC-ADG-2015: ERC Advanced Grant Scope:Objectives

I+D

Cerrada hace 9 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

DWI LEIBNIZINSTITUT FUR INTE...

1.97M€ | Lider

TOP OPTIMIZED TECHNOLOGIES

300.00K€ | Participante

RIJKSUNIVERSITEIT GRONINGEN

529.09K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 69 meses Fecha Inicio: 2016-04-20
Fecha Fin: 2022-01-31

Líder del proyecto

DWI LEIBNIZINSTITUT FUR INTERAKTIVE MATERIALI... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The pharmaceutical sector has a huge demand for new active compounds including natural products to fill the drug pipelines and to stop the global decline in novel approved active pharmaceutical ingredients. Therefore, developing new tools to fabricate complex molecular structures in a fast and reliable way is paramount. This holds especially true for the field of antibiotics. Multidrug resistant (MDR) pathogens evolve at a terrifying rate and confer resistance to all presently available antibacterial treatments and therefore WHO has identified MDR bacteria as major threat to human health. In this ERC Advanced Grant, I propose a radically new approach to fabricate very complex molecules with minimal synthetic effort. The technology is based on nucleic acid binders (aptamers), which are evolved in a selection protocol and block several functional groups within a target molecule while allowing other functionalities not in contact with the aptamer to be selectively modified in a single reaction step. Here, we aim to establish this groundbreaking aptameric protective group (APG) method as a novel tool that gives access to compounds that would otherwise be too difficult to obtain by multistep synthesis. Toward this end, the specific objectives are: • To develop reagents and reactions that are compatible with aptamer-mediated reactions • To control the site of chemical modification within complex molecules by APGs • To establish APGs as a general paradigm in natural product derivatization to modify several kinds of substrates • To achieve site selective modification of proteins by aptamers • To synthesize novel antibiotics that kill MDR bacteria • To fabricate image-and-activate antibiotics by the APG technology • To employ the aptamer-target complexes for live-cell imaging of RNA The outcomes will enable future advances in drug discovery and drug design, bioimaging technologies, and the site-specific modification of therapeutic proteins.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores